A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

This study is testing a combination of two drugs — pemigatinib (a targeted therapy) and retifanlimab (an immunotherapy) — in people with an advanced type of fat cell cancer called dedifferentiated liposarcoma (DDLPS) that has come back or gotten worse after prior treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with DDLPS confirmed by a lab test (with specific gene markers) - Your cancer has grown or returned within the last 6 months despite at least one previous treatment - You have at least one measurable tumor that cannot be removed surgically - Your body is functioning well enough to tolerate treatment (ECOG performance score 0–2) **You may NOT be eligible if...** - You have received cancer treatment within the past 4 weeks - You have had serious lung inflammation (pneumonitis) that required steroids in the past - You have active, untreated cancer spreading to the brain - You have an active autoimmune disease requiring high-dose steroids - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.